drugset
drugset / Trial / NCT00258843

Safety of Imovax Polio in Chinese Infants and Children

NCT00258843 ↗

Phase 3 Completed 40 enrolled Sanofi Pasteur, a Sanofi Company
Non-randomizedSingle-groupOpen-labelPrevention

Summary

To describe the tolerance in terms of occurrence of serious adverse reactions and severe adverse reactions (injection site and systemic) within eight days after one dose of IMOVAX Polio™ administered in children and infants.

Timeline

Start
2005-11
Primary completion
2006-02
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Inactivated Polio Vaccine Vaccine 0.5 ml Intramuscular

Indications

poliomyelitis